Last reviewed · How we verify

NCT06992141: CHIVAS-M1

A Strep Throat Controlled Human Infection Trial in Healthy Adults

Completed EARLY_PHASE1 Last updated 16 March 2026
What this trial tests

EARLY_PHASE1 trial testing Streptococcus pyogenes M1UK strain MCRI0102 in Streptococcus Pyogenes Pharyngitis in 40 participants. Completed in 16 February 2026.

Timeline
24 July 2025
Primary endpoint
31 October 2025
16 February 2026

Quick facts

Lead sponsorMurdoch Childrens Research Institute
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment40
Start date24 July 2025
Primary completion31 October 2025
Estimated completion16 February 2026
Sites1 location across Australia

Drugs / interventions tested

Conditions studied

Sponsor

Murdoch Childrens Research Institute

Who can join

Adults 18 to 40, any sex, with Streptococcus Pyogenes Pharyngitis or Streptococcus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This aim of this study is to further develop a new way to study the bacteria that causes pharyngitis (strep throat). The scientific name for this bacterium is Streptococcus pyogenes and it is commonly known as Strep A. Strep A is a common type of bacteria that can cause various infections. These range from skin infections and strep throat to more serious conditions like rheumatic heart disease. In recent years there has been an increase in severe Strep A infections in most countries. Many of these cases have been reported in the news. Human challenge models are studies which allow researchers to study organisms that cause infections in humans. In this human challenge model study, healthy participants will be carefully exposed to a specific type of Strep A under controlled conditions to cause sore throat and learn more about how Strep A causes infection. The study team has already developed a safe human challenge model using a strain of Strep A called M75. This study will use a different strain of Strep A, called M1. The main goal of this study is to check if the procedure is safe for participants and to understand how the participant's body responds to M1 Strep A. The study will explore: 1. How much M1 Strep A is required to cause an infection. 2. How M1 Strep A grows in the body. 3. How the body reacts to M1 Strep A. The information the investigators will get about M1 Strep A from this study will help plan future research. It may also help in designing better studies to test vaccines against Strep A.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Murdoch Childrens Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06992141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing